Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Fungal Infection Reports
Published in: Current Fungal Infection Reports 4/2017

01-12-2017 | Clinical Mycology Lab Issues (S Córdoba, Section Editor)

Candida haemulonii sensu lato: Update of the Determination of Susceptibility Profile in Argentina and Literature Review

Authors: Guillermina Isla, Constanza G. Taverna, Wanda Szusz, Walter Vivot, Guillermo García-Effron, Graciela Davel

Published in: Current Fungal Infection Reports | Issue 4/2017

Login to get access

Abstract

Purpose of review

This review summarizes the information available of Candida haemulonii sensu lato, and updates the in vitro susceptibility profile of the isolates of these species from Argentina. C. haemulonii sensu lato causes fungemia in low frequency in adults and children; however, the knowledge about this emerging yeast is relevant since it is considered as a multi-resistant pathogen.

Recent findings

The discovery of new antifungal molecules, the determination of epidemiological cutoff value and clinical breakpoints for some yeasts of clinical impact, and the update of techniques to determine the in vitro susceptibility profile to yeast have generated some available information, although, for C. haemulonii sensu lato, this information is not always useful for clinical application.

Summary

We determined the susceptibility profile of C. haemulonii sensu lato strains isolated in Argentina, as a first step to establish the epidemiological cutoff values in our region. We also review the current situation in other countries.
Literature
1.
Cendejas-Bueno E, Kolecka A, Alastruey-Izquierdo A, Theelen B, Groenewald M, Kostrzewa M, et al. Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts. J Clin Microbiol. 2012;50:3641–51.CrossRefPubMedPubMedCentral
2.
Almeida JN Jr, Motta AL, Rossi F, Abdala E, Pierrotti LC, et al. First report of a clinical isolate of Candida haemulonii in Brazil. Clinics. 2012;67:1229–31.CrossRefPubMedPubMedCentral
3.
Khan ZU, Al-Sweih NA, Ahmad S, Al-Kazemi N, Khan S, Joseph L, et al. Outbreak of fungemia among neonates caused by Candida haemulonii resistant to amphotericin B, itraconazole and fluconazole. Clin Microbiol. 2007;45:2025–7.CrossRef
4.
Muro MD, Motta F de A, Burger M, Melo AS, Dalla-Costa LM. Echinocandin resistance in two Candida haemulonii isolates from pediatric patients. J Clin Microbiol. 2012;50:3783–5.
5.
Silva CM, Carvalho-Parahym AM, Macêdo DP, Lima-Neto RG, Francisco EC, Melo AS, et al. Neonatal candidemia caused by Candida haemulonii: case report and review of literature. Mycopathologia. 2015;180:69–73.CrossRefPubMed
6.
Kim MN, Shin JH, Sung H, Lee K, Kim EC, Ryoo N, et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infec Diseases. 2009;48:57–61.CrossRef
7.
Crouzet J, Sotto A, Picard E, Lachaud L, Bourgeois N. A case of Candida haemulonii osteitis: clinical features, biochemical characteristics, and antifungal resistance profile. Clin Microbiol Infect. 2011;17:1068–70.CrossRefPubMed
8.
Yuvaraj A, Rohit A, Koshy PJ, Nagarajan P, Nair S, Abraham G. Rare occurrence of fatal Candida haemulonii peritonitis in a diabetic CAPD patient. Ren Fail. 2014;36:1466–7.CrossRefPubMed
9.
Fang SY, Wei KC, Chen WC, Lee SJ, Yang KC, Wu CS, et al. Primary deep cutaneous candidiasis caused by Candida duobushaemulonii in a 68-year-old man: the first case report and literature review. Mycoses. 2016;Sep:1–4.
10.
• Kumar A, Prakash A, Singh A, Kumar H, Hagen F, Meis JF, et al. Candida haemulonii species complex: an emerging species in India and its genetic diversity assessed with multilocus sequence and amplified fragment-length polymorphism analyses. Emerg Microbes Infect. 2016;25-5:e49. This work contains an important number of strains, and the determination of the MICs was performed following a reference methodology.
11.
Chowdhary A, Anil Kumar V, Sharma C, Prakash A, Agarwal K, Babu R, et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. 2014;33:919–26.CrossRefPubMed
12.
• Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, et al. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol. 2015;53:1823–30. This work contains an important number of strains, and the determination of the MICs was performed following a standard reference method. CrossRefPubMedPubMedCentral
13.
Hou X, Xiao M, Chen SC, Wang H, Cheng JW, Chen XX, et al. Identification and antifungal susceptibility profiles of Candida haemulonii species complex clinical isolates from a multicenter study in China. J Clin Microbiol. 2016;54:2676–80.CrossRefPubMedPubMedCentral
14.
Grenfell RC, da Silva Junior AR, Del Negro GM, Munhoz RB, Gimenes VM, Assis DM, et al. Identification of Candida haemulonii complex species: use of ClinProTools™ to overcome limitations of the Bruker Biotyper™, VITEK MS™ IVD, and VITEK MS™ RUO databases. Front Microbiol. 2016;7:940.CrossRefPubMedPubMedCentral
15.
16.
Kordalewska M, Zhao Y, Lockhart SR, Chowdhary A, Berrio I, Perlin DS. Rapid and accurate molecular identification of the emerging multidrug-resistant pathogen Candida auris. J Clin Microbiol. 2017;55:2445–52.CrossRefPubMedPubMedCentral
17.
Oh BJ, Shin JH, Kim MN, Sung H, Lee K, et al. Biofilm formation and genotyping of Candida haemulonii, Candida pseudohaemulonii, and a proposed new species (Candida auris) isolates from Korea. Med Mycol. 2011;49:98–102.CrossRefPubMed
18.
Rodero L, Cuenca-Estrella M, Córdoba S, Cahn P, Davel G, Kaufman S, et al. Transient fungemia caused by an amphotericin B-resistant isolate of Candida haemulonii. J Clin Microbiol. 2002;40:2266–9.CrossRefPubMedPubMedCentral
19.
Cordoba S, Vivot W, Bosco-Borgeat ME, Taverna C, Szusz W, Murisengo O, et al. Species distribution and susceptibility profile of yeasts isolated from blood cultures: results of a multicenter active laboratory-based surveillance study in Argentina. Rev Argent Microbiol. 2011;43:176–85.PubMed
20.
Nucci M, Queiroz-Telles F, Alvarado-Matute T, Tiraboschi IN, Cortes J, Zurita J, et al. Epidemiology of candidemia in Latin America: a laboratory-based survey. PLoS One. 2013;8:e59373.CrossRefPubMedPubMedCentral
21.
• Santolaya ME, Alvarado T, Queiroz-Telles F, Colombo AL, Zurita J, Tiraboschi IN, et al. Latin American Invasive Mycosis Network. Active surveillance of candidemia in children from Latin America: a key requirement for improving disease outcome. Pediatr Infect Dis J. 2014;33:e40–4. This study was conducted in Latin American countries in children provides information about the epidemiology of yeast infections in region. CrossRefPubMed
22.
Ben-Ami R, Berman J, Novikov A, Bash E, Shachor-Meyouhas Y, Zakin S, et al. Multidrug-resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis. 2017;23:195–203.CrossRefPubMedCentral
23.
Guinea J, Zaragoza O, Escribano P, Martin-Mazuelos E, Peman J, Sanchez-Reus F, et al. Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. Antimicrob Agents Chemother. 2014;58:1529–37.CrossRefPubMedPubMedCentral
24.
Faria-Ramos I, Neves-Maia J, Ricardo E, Santos-Antunes J, Silva AT, Costa-de-Oliveira S, et al. Erratum to: species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey. Eur J Clin Microbiol Infect Dis. 2015;34:2137.CrossRefPubMed
25.
Minea B, Nastasa V, Moraru RF, Kolecka A, Flonta MM, Marincu I, et al. Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study. Eur J Clin Microbiol Infect Dis. 2015;34:367–83.CrossRefPubMed
26.
Meletiadis J, Geertsen E, Curfs-Breuker I, Meis JF, Mouton JW. Intra- and interlaboratory agreement in assessing the in vitro activity of micafungin against common and rare Candida species with the EUCAST, CLSI, and Etest methods. Antimicrob Agents Chemother. 2016;60:6173–8.CrossRefPubMedPubMedCentral
27.
Nucci M, Thompson-Moya L, Guzman-Blanco M, Tiraboschi IN, Cortes JA, Echevarría J, et al. Grupo Proyecto Épico. Recommendations for the management of candidemia in adults in Latin America. Grupo Proyecto Épico. Rev Iberoam Micol. 2013;30:179–88.
28.
Santolaya ME, de Queiroz Telles F, Alvarado Matute T, Colombo AL, Zurita J, Tiraboschi IN, et al. Recommendations for the management of candidemia in children in Latin America. Rev Iberoam Micol. 2013;30:171–8.
29.
•• Pappas PG, Kauffman CA, Andes D, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guidelines for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:1–50. Last update of therapeutic guidelines of candidiasis.
30.
•• European Committee for Antimicrobial Susceptibility Testing (EUCAST) Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts, Eucast Definitive Document E.Def 7.3 January 2017. Methodology applied in this work.
31.
• European Committee on Antimicrobial Susceptibility Testing (EUCAST). Antifungal Agents. Breakpoint tables for interpretation of MICs Version 8.1 valid from 2017–03-01 www.​eucast.​org 2017;1–5. Current Clinical Breakpoint used for the interpretation of MICs.
32.
Kurtzman CP, Fell JW, Boekhout T, editors. The yeast: a taxonomic study. 5th ed. Amsterdam: Elsevier; 2011.
33.
Taverna CG, Bosco-Borgeat ME, Murisengo OA, Davel G, Boité MC, Cupolillo E, et al. Comparative analyses of classical phenotypic method and ribosomal RNA gene sequencing for identification of medically relevant Candida species. Mem Inst Oswaldo Cruz. 2013;108:178–85.CrossRefPubMedPubMedCentral
34.
Schoch CL, Seifert KA, Huhndorf S, Robert V, Spouge JL, Levesque CA, et al. and Fungal Barcoding Consortium Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for Fungi. Proc Natl Acad Sci U S A. 2012;109:6241–6.CrossRefPubMedPubMedCentral
35.
Ciardo DE, Schär G, Böttger EC, Altwegg M, Bosshard PP. Internal transcribed spacer sequencing versus biochemical profiling for identification of medically important yeasts. J Clin Microbiol. 2006;44:77–84.CrossRefPubMedPubMedCentral
36.
Nilsson RH, Kristiansson E, Ryberg M, Hallenberg N, Larsson KH. Intraspecific ITS variability in the kingdom Fungi as expressed in the international sequence databases and its implications for molecular species identification. Evol Bioinformatics Online. 2008;4:193–201.
37.
Kurtzman CP, Piskur J 2005. Taxonomy and phylogenetic diversity among the yeasts. Top Curr Genet 15.
38.
Orasch C, Marchetti O, Garbino J, Schrenzel J, Zimmerli S, Mühlethaler K, et al. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland. Clin Microbiol Infect. 2014;20:698–705.CrossRefPubMed
39.
Ruan SY, Kuo YW, Huang CT, Hsiue HC, Hsueh PR. Infections due to Candida haemulonii: species identification, antifungal susceptibility and outcomes. Antimicrob Agents. 2010;35:85–8.CrossRef
40.
Shin JH, Kim MN, Jang SJ, MY J, Kim SH, Shin MG, et al. Detection of amphotericin B resistance in Candida haemulonii and closely related species by use of the Etest, Vitek-2 yeast susceptibility system, and CLSI and EUCAST broth microdilution methods. J Clin Microbiol. 2012;50:1852–5.CrossRefPubMedPubMedCentral
41.
Garcia-Effron G, Katiyar SK, Park S, Edlind TD, Perlin DS. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2008;52:2305–12.CrossRefPubMedPubMedCentral
42.
• Ramos LS, Figueiredo-Carvalho MH, Barbedo LS, Ziccardi M, Chaves AL, Zancopé-Oliveira RM, et al. Candida haemulonii complex: species identification and antifungal susceptibility profiles of clinical isolates from Brazil. J Antimicrob Chemother. 2015;70(1):111–5. This work contains a significant number of strain; the determination of MICs was developed following a reference methodology and provides the profile of antifungal susceptibility of circulating strains in Latin America. CrossRefPubMed
43.
• de Almeida JN Jr, Assy JG, Levin AS, Del Negro GM, Giudice MC, Tringoni MP, et al. Candida haemulonii Complex Species, Brazil, January 2010–March 2015. Emerg Infect Dis. 2016;22:561–3. This work contains a significant number of strains; the determination of MICs was developed following a reference methodology and provides the profile of susceptibility of circulating strains in Latin America. CrossRefPubMed
44.
Sugita T, Takashima M, Poonwan N, Mekha N. Candida pseudohaemulonii sp. nov., an amphotericin B-and azole-resistant yeast species, isolated from the blood of a patient from Thailand. MicrobiolImmunol. 2006;50:469–73.
45.
Arendrup MC, Prakash A, Meletiadis J, Sharma C, Chowdhary A. Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob Agents Chemother. 2017;24:61.
Metadata
Title
Candida haemulonii sensu lato: Update of the Determination of Susceptibility Profile in Argentina and Literature Review
Authors
Guillermina Isla
Constanza G. Taverna
Wanda Szusz
Walter Vivot
Guillermo García-Effron
Graciela Davel
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Fungal Infection Reports / Issue 4/2017
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-017-0300-y

Other articles of this Issue 4/2017

Current Fungal Infection Reports 4/2017 Go to the issue

Clinical Mycology Lab Issues (S Córdoba, Section Editor)

Detection of Cryptic Candida Species Recognized as Human Pathogens Through Molecular Biology Techniques

Fungal Genomics and Pathogenesis (S Shoham, Section Editor))

Pathogenesis of Invasive Pulmonary Aspergillosis in Transplant Recipients

Fungal Genomics and Pathogenesis (Shmuel Shoham, Section Editor)

What Is New? Recent Knowledge on Fungal Extracellular Vesicles

Current Management of Fungal Infections (M Miceli, Section Editor)

Clinical Implications of Candida Biofilms

Current Management of Fungal Infections (M Miceli, Section Editor)

The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre Approach

Clinical Mycology Lab Issues (S Córdoba, Section Editor)

A Comprehensive Analysis of MALDI-TOF MS and Ribosomal DNA Sequencing for Identification of Clinical Yeasts
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits